ORIGINAL RESEARCH article
Front. Cell. Infect. Microbiol.
Sec. Clinical Infectious Diseases
Volume 15 - 2025 | doi: 10.3389/fcimb.2025.1542707
Predictive survival modelings for HIV-related Cryptococcosis: comparing machine learning approaches
Provisionally accepted- 1Max Planck Institute of Psychiatry (MPI), Munich, Germany
- 2Shanghai Public Health Clinical Center, Fudan University, Shanghai, Shanghai Municipality, China
- 3Shanghai Pulmonary Hospital, School of Medicine, Tongji University, Shanghai, Shanghai Municipality, China
- 4Shenzhen Third People’s Hospital, Shenzhen, Guangdong Province, China
- 5Hubei Jiangxia Laboratory, Wuhan, Hebei Province, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
HIV-associated cryptococcosis is marked by unpredictable disease trajectories and persistently high mortality rates worldwide. Although improved risk stratification and tailored clinical management are urgently needed to enhance patient survival, such strategies remain limited.We analyzed clinical and immunological data from 98 HIV-related cryptococcosis cases, employing machine learning techniques to model disease severity and predict survival outcomes. Our approach included unsupervised clustering, elastic net regularized Cox regression, and random survival forests. Model performance was rigorously assessed using the C-index, Brier score, Calibration and time-dependent AUC, with validation executed through a comprehensive, multi-replicated nested crossvalidation framework.Through cytokine profiling, we identified an immune phenotype characterized by excessive inflammatory response (EXC), associated with greater disease severity, more frequent neurological symptoms, and poorer survival outcomes compared to the other two immune phenotypes, highlighting its potential significance in risk stratification.To further support clinical decision-making, we developed an elastic net regularized Cox regression model, achieving superior predictive accuracy with a mean C-index of 0.78 for 36-month outcomes and a mean Brier score of 0.13, outperforming both random survival forest and traditional Cox models. Time-dependent AUC analysis validated the model's robustness, with AUC values of 0.84 at 12 months and 0.79 at 36 months, indicating its reliability and potential clinical utility.This study presents comprehensive and multidimensional approaches to overcome the challenges commonly encountered in real-world clinical settings. By applying cytokine-based clustering, we illustrate the potential for more nuanced severity stratification, offering a fresh perspective on disease progression. In parallel, our penalized survival model provides a step forward in personalized risk assessment, supporting informed clinical decisions and customized patient management. These findings suggest promising directions for individualized healthcare solutions, leveraging machine learning to enhance survival predictions in HIV-related cryptococcosis.
Keywords: HIV, Cryptococcosis, machine learning, Survival Prediction, cytokine, Penalized cox regression
Received: 10 Dec 2024; Accepted: 07 Apr 2025.
Copyright: © 2025 Fu, Wu, Xun, Pütz, Zheng, Li, Shen, Lu, Chen and Müller-Myhsok. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Bertram Müller-Myhsok, Max Planck Institute of Psychiatry (MPI), Munich, Germany
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.